Meeting
2021 Genitourinary Cancers Symposium
Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).
Authors
Arlene O. Siefker-Radtke
The University of Texas MD Anderson Cancer Center, Houston, TX
Arlene O. Siefker-Radtke , Andrea Necchi , Se Hoon Park , Jesús García-Donas , Robert A Huddart , Earle F Burgess , Mark T. Fleming , Arash Rezazadeh , Begona Mellado , Sergei Varlamov , Monika Joshi , Ignacio Duran , Scott T. Tagawa , Yousef Zakharia , Keqin Qi , Manish Monga , Manu Sondhi , Anne OHagan , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02365597
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 426)
DOI
10.1200/JCO.2021.39.6_suppl.426
Abstract #
426
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.
First Author: Arlene O. Siefker-Radtke
Poster
2018 Genitourinary Cancers Symposium
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
First Author: Yohann Loriot
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi
Poster
2022 ASCO Annual Meeting
A phase III randomized trial of eribulin (E) with or without gemcitabine versus standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
First Author: Sarmad Sadeghi